

Title (en)  
5-ALKYLPYRIDO [2,3-D] PYRIMIDINES TYROSINE KINASE INHIBITORS

Title (de)  
5-ALKYLPYRIDO [2,3-D] PYRIMIDIN TYROSINE KINASE INHIBITOREN

Title (fr)  
INHIBITEURS DE TYROSINE KINASE A BASE DE 5-ALKYLPYRIDO [2,3-D] PYRIMIDINES

Publication  
**EP 1268476 A1 20030102 (EN)**

Application  
**EP 01905114 A 20010129**

Priority  
• US 0102657 W 20010129  
• US 18712400 P 20000306

Abstract (en)  
[origin: WO0170741A1] Disclosed are compounds of the formula (I) wherein: R<2> is hydrogen, alkyl, or cycloalkyl; R<3> is hydrogen, lower alkyl, lower alkoxy, halogen, trifluoromethyl, lower alkynyl, lower alkenyl, nitrile, nitro, -COR<4>, -CO2R<4>, -CONR<4>R<5>, -CONR<4>OR<5>, -SO2NR<4>R<5>, -SO2NR<4>R<5>, -SO2R<4>, -SO3R<4>, formula (II), or -NR<4>R<5>; Y is N or CR<7>; R<9> is lower alkyl, haloalkyl, or aryl; X and Z are independently hydrogen, halogen, lower alkyl, lower alkoxy, trifluoromethyl, hydroxy, nitrile, nitro, -NR<4>R<5>, -N(O)R<4>R<5>, -NR<4>R<5>R<6>W, -SR<4>, -C(O)R<4>, -CO2R<4>, -CONR<4>R<5>, -SO2NR<4>R<5>, -SO2R<4>, -SO3R<4>, P(O)(OR<4>)(OR<5>), -T(CH2)mQR<4>, -C(O)T(CH2)mQR<4>, or -NR<4>C(O)T(CH2)mQR<5>; m is 1 to 6. These compounds are useful for treating cell proliferative disorders, such as cancer, atherosclerosis, and restenosis. These compounds are potent inhibitors of cyclin-dependent kinases (cdks) and growth factor-mediated kinases.

IPC 1-7  
**C07D 471/04**; **A61K 31/505**

IPC 8 full level  
**A61K 31/505** (2006.01); **A61K 31/519** (2006.01); **A61K 31/5375** (2006.01); **A61K 31/551** (2006.01); **A61P 9/10** (2006.01); **A61P 17/06** (2006.01); **A61P 35/00** (2006.01); **A61P 43/00** (2006.01); **C07D 471/04** (2006.01)

IPC 8 main group level  
**A61K** (2006.01); **C07D** (2006.01)

CPC (source: EP KR)  
**A61P 9/10** (2017.12 - EP); **A61P 17/06** (2017.12 - EP); **A61P 29/02** (2017.12 - EP); **A61P 35/00** (2017.12 - EP); **A61P 43/00** (2017.12 - EP); **C07D 471/04** (2013.01 - EP KR)

Citation (search report)  
See references of WO 0170741A1

Designated contracting state (EPC)  
AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE TR

Designated extension state (EPC)  
AL LT LV MK RO SI

DOCDB simple family (publication)  
**WO 0170741 A1 20010927**; AP 2002002643 A0 20021231; AR 034119 A1 20040204; AU 3302801 A 20011003; BG 107161 A 20030630; BR 0109056 A 20030603; CA 2401368 A1 20010927; CN 1422268 A 20030604; CO 5280200 A1 20030530; CR 6736 A 20040310; CZ 20022929 A3 20030212; DZ 3308 A1 20010927; EA 200200802 A1 20030227; EE 200200506 A 20040216; EP 1268476 A1 20030102; GT 200100037 A 20020304; HN 2001000040 A 20010906; HR P20020798 A2 20040229; HU P0300136 A2 20030528; IL 151480 A0 20030410; IS 6524 A 20020823; JP 2003528101 A 20030924; KR 20020075805 A 20021005; MA 26881 A1 20041220; MX PA02008535 A 20021213; NO 20024235 D0 20020905; NO 20024235 L 20021105; NZ 520962 A 20030926; OA 12227 A 20040318; PA 8513201 A1 20030630; PE 20011177 A1 20011123; PL 358271 A1 20040809; SK 12472002 A3 20030401; SV 2001000338 A 20011130; TN SN01036 A1 20051110; YU 66502 A 20050919; ZA 200207110 B 20031204

DOCDB simple family (application)  
**US 0102657 W 20010129**; AP 2002002643 A 20010129; AR P010101039 A 20010305; AU 3302801 A 20010129; BG 10716102 A 20021002; BR 0109056 A 20010129; CA 2401368 A 20010129; CN 01807590 A 20010129; CO 01017398 A 20010305; CR 6736 A 20020823; CZ 20022929 A 20010129; DZ 013308 A 20010129; EA 200200802 A 20010129; EE P200200506 A 20010129; EP 01905114 A 20010129; GT 200100037 A 20010305; HN 2001000040 A 20010305; HR P20020798 A 20021004; HU P0300136 A 20010129; IL 15148001 A 20010129; IS 6524 A 20020823; JP 2001568942 A 20010129; KR 20027011627 A 20020905; MA 26801 A 20020904; MX PA02008535 A 20010129; NO 20024235 A 20020905; NZ 52096201 A 20010129; OA 1200200281 A 20010129; PA 8513201 A 20010305; PE 2001000216 A 20010305; PL 35827101 A 20010129; SK 12472002 A 20010129; SV 2001000338 A 20010305; TN SN01036 A 20010302; YU P66502 A 20010129; ZA 200207110 A 20020904